GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kailera Therapeutics, Inc. Common Stock KLRA · USD

US listing · 🇺🇸 United States

Compare

13.70

+5.63%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kailera Therapeutics, Inc. Common Stock

Its shares trade under the ticker KLRA. It has been listed since 17 April 2026.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
17 Apr 2026
Website
kailera.com ↗
Head office
180 THIRD AVENUE, WALTHAM, MA, 02451
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Kailera Therapeutics' pipeline includes KAI-9531, an injectable GLP-1/GIP dual agonist for obesity treatment.
  • The company holds exclusive global rights for four metabolic disease assets outside Greater China.
  • KAI-4729, an injectable tri-agonist, targets obesity and related conditions with dual receptor action.

Weaknesses

  • Kailera Therapeutics is a clinical-stage company with no approved products as of 2026.
  • The company's pipeline relies on injectable and oral peptide therapies with potential delivery challenges.
  • Kailera Therapeutics has limited commercial experience as a 2024-founded biopharmaceutical firm.

Opportunities

  • The obesity treatment market in the US offers significant growth potential for KAI-7535, an oral GLP-1 agonist.
  • KAI-9531's dual agonist mechanism may capture a larger market share in obesity therapies.
  • Expanding into global markets outside Greater China presents opportunities for KAI-4729's tri-agonist therapy.

Threats

  • Competition from established obesity therapies like Wegovy and Mounjaro may impact KAI-9531's market entry.
  • Regulatory hurdles in the US clinical trial process could delay KAI-7535's approval timeline.
  • Market saturation in the obesity treatment sector may reduce KAI-4729's potential revenue growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.